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Towards personalised allele-specific 
CRISPR gene editing to treat 
autosomal dominant disorders
Kathleen A. Christie1, David G. Courtney1, Larry A. DeDionisio  2, Connie Chao Shern  2, 
Shyamasree De Majumdar1, Laura C. Mairs1, M. Andrew Nesbit1 & C. B. Tara Moore1,2
CRISPR/Cas9 holds immense potential to treat a range of genetic disorders. Allele-specific gene 
disruption induced by non-homologous end-joining (NHEJ) DNA repair offers a potential treatment 
option for autosomal dominant disease. Here, we successfully delivered a plasmid encoding S. pyogenes 
Cas9 and sgRNA to the corneal epithelium by intrastromal injection and acheived long-term knockdown 
of a corneal epithelial reporter gene, demonstrating gene disruption via NHEJ in vivo. In addition, 
we used TGFBI corneal dystrophies as a model of autosomal dominant disease to assess the use of 
CRISPR/Cas9 in two allele-specific systems, comparing cleavage using a SNP-derived PAM to a guide 
specific approach. In vitro, cleavage via a SNP-derived PAM was found to confer stringent allele-specific 
cleavage, while a guide-specific approach lacked the ability to distinguish between the wild-type and 
mutant alleles. The failings of the guide-specific approach highlights the necessity for meticulous guide 
design and assessment, as various degrees of allele-specificity are achieved depending on the guide 
sequence employed. A major concern for the use of CRISPR/Cas9 is its tendency to cleave DNA non-
specifically at “off-target” sites. Confirmation that S. pyogenes Cas9 lacks the specificity to discriminate 
between alleles differing by a single base-pair regardless of the position in the guide is demonstrated.
The promise of personalised gene therapy has been brought nearer fruition with the recent advances in the field 
of genome engineering, particularly the development of Clustered Regularly Interspaced Palindromic Repeats 
(CRISPR)/CRISPR associated protein (Cas) systems. CRISPR/Cas9 is an RNA guided endonuclease, that has 
been manipulated for use in mammalian cells to act as a two component system, requiring only a Cas9 nuclease 
and a single guide RNA (sgRNA)1–3. Cas9 can be directed to cut a desired sequence in the genome, provided it is 
directly upstream of a protospacer adjacent motif (PAM), by simply altering the guide RNA sequence (Fig. 1a). 
The site-specific sgRNA will direct the Cas9 nuclease to make a double strand break (DSB). The cell will then 
attempt to repair this damage, by either error-prone non-homologous end joining (NHEJ) or precise homology 
directed repair (HDR)4, and it is by these different cellular responses that different forms of gene editing can be 
achieved.
NHEJ can be utilised to generate gene knockouts, due to the high frequency of frameshifting mutations gen-
erated4,5. Allele-specific gene disruption via NHEJ is a potential approach to treat dominant negative disorders, in 
which the causative gene is haplosufficient; this involves targeting the mutant allele alone for disruption, leaving 
the wild-type allele intact and restoring the phenotype6–9. This approach relies on the ability of the targeting sys-
tem to unequivocally discriminate between wild-type and mutant sequence.
Although CRISPR/Cas9 holds immense promise, one caveat to the use of the system is that Cas9 nuclease has 
been shown to tolerate mismatches between the guide sequence and the target10,11. This can lead to off-targeting 
elsewhere in the genome or, indeed in this case, cleavage of the wild-type allele. Efforts have been made to increase 
the specificity of Cas9 and eliminate off-target cutting, including; use of truncated guides12, Cas9 variants from 
other bacterial species to exploit more intricate PAMs13, rationally engineering the Cas9 nuclease14, and using the 
mutant sequence to induce specificity such as utilising a novel SNP-derived PAM15,16.
In particular utilising a novel PAM is an attractive option for allele-specific editing. Previous work has demon-
strated that when mutations result in a novel PAM, guide RNAs can be designed, utilising this new PAM, allowing 
only the mutant allele to be targeted, producing an allele-specific knockout14.
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The cornea offers an ideal platform for testing personalised gene therapy, due to its immediate accessibility, 
small surface area and immune-privileged status. Collectively the corneal dystrophies represent a group of inher-
itable blinding diseases that alter the shape or transparency of the cornea. Currently mutations in 14 genes are 
associated with corneal dystrophies, 9 of them presenting with an autosomal dominant inheritance pattern17. 
Corneal dystrophies linked to these 9 genes predominantly result from missense mutations or small in-frame 
insertions or deletions that cause disease by a dominant negative effect of the mutant protein17.
Transforming growth factor beta induced protein (TGFBIp) has been linked to a range of stromal or 
stromal-epithelial corneal dystrophies18–20. TGFBI is predominantly produced in the corneal epithelium and is 
transported to the stromal layer, where the mutant protein accumulates21. To-date a total of 60 missense muta-
tions in TGFBI have been linked to various corneal dystrophies22,23. These mutations span the entire TGFBI gene 
but are clustered in hotspots found in exon 4, 11, 12 and 14.
Despite the wide spectrum of mutations, the vast majority of cases are due to 5 prevalent mutations found 
in either codon 124 (exon 4) or codon 555 (exon 12)24,25 (Fig. 1b). These 5 mutations include; R124C, R124H, 
R124L, R555Q and R555W and as described account for the bulk of reported cases of TGFBI corneal dystro-
phies26–28. Remarkably, each of these mutations, differing by only a single amino acid, result in strikingly different 
protein aggregates with a very strong genotype-phenotype correlation.
To achieve complete allele-specificity for a particular TGFBI mutation, stringent fidelity is required as an 
almost perfect off-target site exists in the form of the wild-type allele, which, for the majority of TGFBI mutations, 
differs by only one base pair from the mutant. This report uses TGFBI corneal dystrophies as a model of auto-
somal dominant disease to assess the specificity of the CRISPR/Cas9 system for autosomal dominant disorders. 
An allele-specific approach to target the five most prevalent TGFBI corneal dystrophy mutations is investigated, 
which highlights the promiscuity of Cas9 and the need for a validated, highly specific approach, that will encom-
pass all possible TGFBI mutations.
Results
In vivo corneal gene disruption induced by CRISPR/Cas9 gene editing and NHEJ-mediated DNA 
repair. We utilised a previously reported reporter knock-in mouse (Krt12+/luc2), that exclusively expresses 
firefly luciferase (luc2) in the corneal epithelium under control of the keratin K12 promoter, to study corneal 
delivery and activity of CRISPR/Cas9-mediated gene editing in living animals. To target the luciferase gene, an 
sgRNA utilising a PAM site 61 nucleotides downstream of the luc2 start codon was designed (Fig. 2a) and val-
idated using a dual-luciferase assay (Fig. 2b). Therapeutic efficacy of this CRISPR/Cas9 system in living cornea 
was assessed following a single intrastromal injection in Krt12+/luc2 mice. Luciferase activity was evaluated with 
daily measurements up to 1 week following injection and weekly thereafter, for an additional 5 weeks (Fig. 2c). 
Luciferase activity was significantly reduced from post-injection day 1, with maximal silencing of >99% achieved 
Figure 1. S. pyogenes Cas9 to treat dominant negative TGFBI corneal dystrophies. (a) Cas9 (purple outline) 
can be directed to cut any sequence in the genome (DNA target in grey), provided it is directly upstream of 
a protospacer adjacent motif known as PAM (pink box). This can be achieved by altering the 20 nucleotide 
guide sequence, which is associated with a 82 nucleotide scaffold. (b) 5 prevalent TGFBI mutations and their 
associated corneal dystrophy and codon change. (c) Schematic of the position of the 60 missense mutations 
across the TGFBI gene. The hotspots at exons 4, 11, 12 and 14 are evident, with exons 4 and 12 expanded to 
show the location of the 5 most prevalent TGFBI mutations; R124C, R124H, R125L, R555Q and R555W.
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at day 3 in one animal, and a maximal mean reduction of 82% ± 13% observed in 4 mice on day 4. Sustained 
silencing of luciferase expression was observed in 3 out of 4 mice over the entire monitoring period of the experi-
ment (7 weeks), while in the remaining animal, luciferase inhibition persisted for 2 weeks (Fig. 2c).
Mutational analysis of TGFBI corneal dystrophy mutations. Currently the best characterised 
CRISPR/Cas9 system is that of Streptococcus pyogenes (SpCas9), which recognises a 5′-NGG-3′ PAM. An analysis 
of the 60 known TGFBI missense mutations (See Supplementary Table 1) was performed to determine if i) they 
generate a novel S. pyogenes PAM or ii) they have a S. pyogenes PAM nearby, placing the mutation within the seed 
region, defined here as the first 8 nucleotides immediately adjacent to the PAM29–31.
19/60 mutations generate a novel S. pyogenes PAM, while 44/60 have a naturally occurring adjacent PAM site 
that places the mutation within an eight nucleotide seed region. When these figures are considered together, 20% 
of the TGFBI missense mutations are not targetable by S. pyogenes (Fig. 3a).
Analysis of the most prevalent TGFBI mutations in codon 124 and codon 555 revealed that none generated 
a novel S. pyogenes PAM, however all mutations had a S. pyogenes PAM within the first eight nucleotides of the 
target sequence (Fig. 3b).
Further to this, an analysis was conducted to determine if any of the prevalent TGFBI mutations generated 
a novel PAM with a CRISPR system from a different bacterial species. It was found that the R555W mutation 
generated a novel PAM with Staphylococcus aureus Cas9 (SaCas9), which recognises a 5′-NNGRRT-3′ PAM. In 
addition to this the R124L mutation generated a novel PAM with a mutant Acidaminococcus Cpf1 (AsCpf1) sys-
tem32, which is capable of recognising a 5′-VYCV-3′ PAM (Fig. 3c).
Validation of an S. pyogenes Cas9 PAM-specific approach. A PAM-specific approach has previously 
been shown to be an ideal way to achieve allele-specific editing14. To validate this approach a lattice corneal 
dystrophy-associated TGFBI mutation (L527R), was assessed33. The L527R mutation (c.1580 T > G) gener-
ates a novel PAM with S. pyogenes, (CTG > CGG) (Fig. 4a, top). A 20 nt sgRNA utilising the novel PAM was 
designed and an additional 20 nt sgRNA targeted to a naturally occurring PAM was designed as a positive control 
(Fig. 4a, bottom). Specificity was first assessed using a previously described in vitro dual-luciferase assay7,9,34 in 
Figure 2. Sustained CRISPR/Cas9 mediated silencing of luc2 in vivo. (a) The short guide RNA (sgRNA) 
specific for luc2 was designed to target the 5′ region of the gene, to increase the likelihood of inducing a frame-
shifting deletion that would knock out luciferase activity by generating a premature termination codon. (b) An 
in vitro dual-luciferase assay demonstrated successful targeting of luc2 by the sgLuc2 construct, as shown by 
a significant reduction in luciferase activity when normalized to untreated cells (data normalised against the 
untreated control = 100%). (c) Representative image of mice displaying a maximal reduction in luc2 expression 
after injection with the sgLuc2 construct (right eye). This image was taken from the mouse represented by the 
green line in panel (d), below, at 7 days post treatment. (d) After treatment, the corneal luciferase activity of 
each mouse was quantified using a Xenogen IVIS live animal imager every day for 7 days, then every 7 days 
thereafter, for a total of 6 weeks. Luciferase activity for each treatment group expressed as a percentage of control 
(R/L ratio %).
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which the two sgRNAs were co-expressed with either S. pyogenes Cas9, S.aureus Cas9 or AsCpf1 and a luciferase 
reporter containing a 50 bp region of either wild -type or mutant TGFBI sequence, which has been cloned into the 
multiple-cloning-site within the 3′UTR of Luc2. Cleavage of the TGFBI sequence within the reporter construct 
prevents transcription and processing of luciferase mRNA and results in an proportionate reduction of luciferase 
expression and therefore luciferase activity was measured as an indicator of sgRNA activity. The sgRNA utilising 
the novel PAM was shown to be highly specific, directing cutting of only the mutant TGFBI sequence, while 
both reporters were cleaved by the common sgRNA (Fig. 4b). In addition, an in vitro digestion using mutant 18 
and 20 nt sgRNAs with a reporter containing either wild-type or mutant TGFBI sequence was carried out which 
confirmed the specificity observed in the dual-luciferase assay (Fig. 4c). Co-transfection with the mutant 18 and 
20 nt sgRNAs only resulted in cleavage of the mutant reporter, the wild-type reporter template remained intact. 
Truncation of the guide did not appear to improve specificity.
Investigation of Cas9 orthologues S.aureus and AsCpf1. As none of the prevalent TGFBI mutations 
generated a novel PAM with S. pyogenes Cas9, alternative Cas9 orthologues were investigated. Although S.aureus 
Cas9 prefers a 5′-NNGRRT-3′ PAM, generated by the TGFBI R555W mutation (5′-GAGAAT-3′) (Fig. 3b). It has 
also been shown to recognise a 5′-NNGRRV-3′ PAM with comparable efficiencies35, and this is present in the 
wild-type TGFBI sequence. Since S.aureus Cas9 prefers a guide length of either 21 nucleotides or 22 nucleotides13. 
both 21 nt and 22 nt guides utilising the novel S.aureus PAM were designed and targeted to both wild-type and 
mutant R555W TGFBI sequences. No significant knockdown was observed with either guide length and the 
mutant R555W guide was unable to distinguish between wild-type and mutant TGFBI sequence (Fig. 5a).
A mutant AsCpf1 was generated that has the capability of recognising a 5′-VYVC-3′ PAM, as generated by the 
TGFBI R124L mutation (5′-CTCA-3′) (Fig. 3b). A 20 nt guide was designed utilising the novel mutant AsCpf1 
PAM and targeted to both the wild-type and mutant R124L TGFBI sequences. Although the mutant guide can 
distinguish between wild-type and mutant TGFBI sequence the knockdown efficiency is very low with a maximal 
knockdown of 20% (Fig. 5b).
Investigation of a guide-specific approach using S. pyogenes Cas9. As none of the most prevalent 
TGFBI mutations generated a novel PAM with S. pyogenes Cas9 and adequate specificity or efficiency could not 
Figure 3. Analysis of TGFBI corneal dystrophy mutations in a CRISPR system Codons 124 or 555 shown in 
green, mutated base shown in red, nearest PAM to be utilised shown in blue and consequential guide sequence 
shown in orange. (a) Mutation analysis revealed that none of the prevalent TGFBI mutations generated a novel 
S. pyogenes PAM, however a naturally occurring PAM exists for all five mutations. For mutations in codon 
124 the nearest downstream PAM places the mutated base at either position 3 or 4 of the guide sequence. For 
mutations in codon 555 the nearest downstream PAM places the mutated base at either position 7 or 8 of the 
guide sequence. (b) Mutational analysis revealed that R124L generates a novel PAM with a mutant AsCpf1 that 
recognises a 5′-VYCV-3′ PAM. R124L generates a 5′-CTCA-3′ PAM. Further analysis revealed that R555W 
generates a novel PAM with S.aureus which is capable of recognising a 5′-NNGRRT-3′ PAM. R555W generates 
a 5′-GAGAAT-3′ PAM. (c) Venn diagram to illustrate the total number of TGFBI mutations that (i) generate a 
novel S. pyogenes PAM, (ii) have a near-by S. pyogenes PAM i.e. within the first 8 bp of the guide sequence, (iii) 
have both a novel and near-by S. pyogenes PAM or (iv) are not targetable by either approach.
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Figure 4. Allele-specific cleavage of L527R TGFBI mutation utilising a PAM-specific approach. (a) The L527R 
mutation (c.1580 T > G) is indicated in red and PAM utilised is shown in green. A 20 nt sgRNA targeted to 
a naturally occurring PAM was designed as a positive control (sgWT, purple –top of figure). A 20 nt sgRNA 
utilising the novel PAM, containing the L527R mutation, was designed (sgMUTANT, blue – bottom of figure). 
(b) Both sgWT and sgMUTANT were targeted to a luciferase reporter plasmid containing either a wild-type or 
mutant TGFBI sequence to determine potency and allele specificity. (c) An in vitro digestion with Cas9 protein 
complexed with a sgRNA utilising the novel L527R PAM was carried out to confirm the specificity observed. 
Mutant guides of both 20 and 18 nucleotides were tested. Uncropped gel images are available in Supplementary 
Figure 1.
Figure 5. Evaluation of Cas9 orthologues in a PAM-specific system targeted to prevalent TGFBI mutations 
Guide RNA tested shown in purple, PAM utilised shown in green and mutation shown in red. (a) 22 and 21 
nucleotide guides were designed to target the novel S.aureus Cas9 PAM generated by R555W. Both guide 
lengths were targeted to a luciferase reporter plasmid containing either a wild-type or mutant TGFBI sequence 
to determine potency and allele specificity. (b) A guide utilising the novel mutant AsCpf1 PAM generated by 
R124L was targeted to a luciferase reporter plasmid containing either a wild-type or mutant TGFBI sequence to 
determine potency and allele specificity.
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be achieved with Cas9 orthologues from other bacterial species, a guide-specific approach was explored; whereby 
the mutant guide differs from the wild-type sequence only by a single base pair. A dual-luciferase assay was 
employed to assess the specificity of a 20 nt guide for the 5 most prevalent TGFBI mutations; R124C, R124H, 
R124L, R555Q and R555W. Each guide was targeted to the wild-type and respective mutant sequence and the 
firefly luciferase activity was measured as an indicator of specificity (Fig. 6).
Cas9 directed by R124C sgRNA was able distinguish between wild-type and mutant sequence, although it cut 
with a low efficiency of 26%. R124H cut with an improved specificity and efficiency, although wild-type sequence 
was significantly cleaved (17%). R124L offered the most promising specificity profile, 60% cleavage of mutant 
sequence was observed in comparison to 23% of the wild-type sequence, however the wild-type sequence was 
still significantly cleaved when compared to the non-specific control. Although the R555Q guide directed efficient 
cleavage of the mutant reporter, the wild-type sequence was also substantially cut by 50%. Finally R555W prefer-
entially cleaved mutant sequence, however the wild-type sequence was still cleaved by 10%.
Investigation of the effect of guide length on the specificity of S. pyogenes Cas9. Reports have 
indicated that truncating the length of the matching sequence within the guide to 18 nucleotides can reduce 
off-target cutting, while maintaining on-target efficiencies12. As none of the 20 nt guides provided adequate spec-
ificity an assessment of the effect of guide-length upon specificity using a dual-luciferase assay was conducted 
for the 5 most prevalent TGFBI mutations. Reports have shown that guide lengths <16 nt abolish cleavage activ-
ity36,37. For each mutation a range of guide lengths from 16–22 nucleotides were tested, each guide was targeted 
to the wild-type and respective mutant sequence and the firefly luciferase activity was measured as an indicator 
of specificity (Fig. 7).
For all mutations investigated the truncated guides did not provide a marked improvement of specificity, for 
most cases maximal discrimination occurred with guides 20 or 19 nucleotides in length. For R124C, a 20 nt guide 
seemed to confer allele-specificity, however no other guide length offered any adequate discrimination (Fig. 7a). 
In the case of the R555Q mutation guides in the 18–20 nt range did not offer sufficient discrimination, although, 
interestingly, the 21 nt guide provided convincing allele-specificity (Fig. 7d). R555W did not offer any consid-
erable allele-specificity for any length tested (Fig. 7e). R124H and R124L displayed clear allele-specific cleavage, 
especially in the 18–20 nt sgRNA range, with minimal cutting of the wild-type sequence (Fig. 7b,c). Interestingly 
for the R124 mutations guide lengths of 21 nt seemed to impair cleavage activity in all cases.
Addition of 5′-GG to the 20 nt guide sequence. Standard design of sgRNA guides includes the addition 
of a guanine to the 5′ end of the guide sequence (5′-GX20-3′) to help facilitate efficient transcription4. An alter-
native guide design of 5′-GGX20-3′ has been reported to minimise off-target activity in certain cases, offering an 
improved specificity of Cas938. This parameter was tested using the 5 most prevalent TGFBI mutations (Fig. 8). 
The additional guanine at the 5′ end of the guide sequence did not provide an improved specificity in any case. 
In some instances a reduction in on-target activity was observed, confirming that specificity is guide dependent.
In vitro digestion to confirm specificity of S. pyogenes Cas9. In vitro digestion of either wild-type or 
mutant TGFBI sequence with Cas9 protein complexed with sgRNA was carried out to further assess the specific-
ity profile of S. pyogenes Cas9 (Fig. 9). Guide lengths of 18 and 20 nucleotides were tested to evaluate the impact 
of truncating the guide sequence. For R124C the mutant 20 nt guide appeared to cut the mutant sequence more 
than the wild-type sequence. However, when truncated to 18 nt the mutant guide appeared to loose ability to 
distinguish between wild-type and mutant sequence, reflecting results from the dual luciferase assay. For R124H 
and R124L both mutant 20 nt and 18 nt guides appeared to clearly cut the mutant sequence preferentially over the 
wild-type sequence, again reflecting the dual-luciferase results. Interestingly, in both cases the wild-type guide 
appeared to result in more cleavage of the mutant sequence in comparison to the mutant sequence, although as 
the wild-type guide would not be implicated in a clinical setting it can be ignored. For R555Q and R555W the 
20 nt or 18 nt guides did not confer allele-specificity under any conditions, cutting both wild-type and mutant 
Figure 6. Investigation of a guide-specific approach to treat prevalent TGFBI mutations Using a guide-specific 
approach, 20 nucleotide guides for the 5 most prevalent TGFBI mutations (as shown in Fig. 3a) were targeted 
to wild-type and respective mutant sequence in a dual luciferase assay. The 5 guides cut with varying degrees of 
specificities and efficiencies. There was a significant difference between the wild-type and mutant sequence in all 
cases.
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sequence equally, demonstrating mismatches in the distal region of the guide are less critical in determining 
specificity of Cas9.
Discussion
Dominant negative disorders that are the result of an accumulation of mutant protein can be targeted by 
allele-specific CRISPR mediated gene disruption via NHEJ. We have shown in vivo that gene disruption via NHEJ 
offers a viable approach to achieve gene silencing. Sustained knockdown of luciferase was observed in the corneal 
epithelium of reporter mice over several weeks in 3 out of 4 mice, following a single intrastromal injection of 
CRISPR/Cas9 components (Fig. 2c). Since the corneal epithelium is completely turned over every 1–2 weeks39, 
our data suggests permanent editing took place within the corneal stem cell compartment following in vivo deliv-
ery of CRISPR/Cas9. By extension, CRISPR/Cas9 gene editing using an sgRNA specific to pathologic mutant 
alleles delivered by intrastromal injection has great potential for editing resident corneal stem cells as a perma-
nent cure for dominant-negative corneal disorders. However, in order to translate this strategy to the clinic as a 
therapy the issue of specificity must be addressed.
The prevalent TGFBI mutations offer an interesting real-life scenario in which to test different approaches to 
allele-specific CRISPR/Cas9 gene therapy as the different causative mutations with different phenotypes associ-
ated with the same codon create different specificity profiles.
Figure 7. Guide-length screen to determine the effect on specificity of a guide-specific system Heatmaps 
showing varying degrees of knockdown observed via a dual luciferase assay when guides ranging in different 
lengths are targeted to the wild-type and respective mutant sequence. Specificity bars show knockdown when 
normalised to the non-specific control, with 100% being maximal knockdown observed. Maximal allele-
specificity observed for each mutation indicated with a red arrow.
Figure 8. Effect of the addition of 5′-GG to the 20 nt guide sequence on specificity 5′-GG was prefixed to the 
20 nucleotide guides for the 5 most prevalent TGFBI mutations (as shown in Fig. 3a) were targeted to wild-type 
and respective mutant sequence in a dual luciferase assay. The addition of 5′-GG did not improve specificity, in 
some cases it caused a reduction in on-target activity.
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Published reports illustrate that the region immediately adjacent to the PAM is critical to specificity25–27. The 
documented importance of this region has led to it being coined as the ‘seed’ region. The Cas9:sgRNA complex 
will initially identify the correct PAM, and only once the PAM has been identified will the Cas9:sgRNA complex 
then test the complementarity between the guide and target DNA. The PAM proximal region, or seed region, is 
critical in this step and mismatches in this region will prevent the ternary complex forming and therefore cleavage 
will not occur40. The exact length of the seed region is unclear, with reports ranging from 5–12 nucleotides29–31.
The TGFBI mutations investigated here gave the opportunity to investigate the extent of this seed region fur-
ther. The mutations in codon 124 lie at guide positions 3 or 4, so are within the seed region of whichever defini-
tion, whereas, codon 555 mutations lie in guide positions 7 or 8, so can be considered either inside or outside the 
seed region. Accordingly, it was demonstrated that allele-specificity was achieved by guides targeting R124H and 
R124L mutations both found at position 3 of the guide. However, neither R124C, R555Q or R555W mutations 
found at positions 4, 7 and 8 respectively, were capable of adequate allele-specific cleavage. This confirms that 
the sequence immediately adjacent to the PAM is most critical in determining specificity of the guide, and mis-
matches are not well tolerated here. In contrast mismatches in positions 4, 7 or 8 of the guide are better tolerated 
and do not have as strong an influence on the fidelity of the guide41.
In addition, it has been demonstrated that U-rich seeds are linked with a low knockdown efficiency, due to 
RNA polymerase III being terminated by U-rich sequences. Interestingly, the R555W mutation in which minimal 
knockdown was observed has a very U-rich seed with 4 U’s within the first 6 bp: 3′-UCUCUU-5′30. Jiang et al. 
reported that mutations in positions ranging from position 1 in the guide to position 6 of the guide sequence 
abolish cleavage activity, except mutations at position 341. These TGFBI results directly contradict this, as the 
R124H and R124L mutations exhibit clear allele-specific cleavage and both mutations are present at position 3 
Figure 9. Confirmation of the specificity achieved using a guide-specific system targeted to prevalent TGFBI 
mutations In vitro digestion of either wild-type or respective mutant TGFBI sequence via Cas9 protein 
complexed with an sgRNA. Guides lengths of 20 and 18 nucleotides were assessed. Uncropped gel images are 
available in Supplementary Figure 2.
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of the guide. Therefore, it is evident that restrictions most likely vary from one guide sequence to another and in 
each case should be individually assessed.
That single mismatches in guide sequences can be tolerated regardless of their position in the guide has 
been confirmed in other reports11,42,38. Contrary to initial reports using other genes, manipulation of the guide 
sequence, in the form of truncation or addition of extra guanine bases, did not provide improved specificity in any 
case. This is consistent with follow up reports that demonstrate truncated guides or additional guanines do not 
offer improved specificity in most cases42,43. An intriguing observation was that for all R124 mutations the guide 
length of 21 nt seemed to impair cleavage activity, it is unclear why this happens but we hypothesise it may alter 
structure of stability of the sgRNA.
To confirm whether the results observed in vitro could be directly translated to a real-life scenario, it would 
be compelling to test these guides ex vivo in patient derived primary cells or in vivo in a mutation-specific ani-
mal model. This would demonstrate the effectiveness of a combined in vitro dual-luciferase and cleavage assay 
as a preliminary screening stage to ensure guides with adequate specificity are utilised downstream in a clinical 
setting.
The use of CRISPR therefore has clear limitations in targeting specific disease-causing mutations. In circum-
stances when one is not tied to targeting a specific disease-causing mutation, the criteria for selecting an appro-
priate sgRNA can be outlined as; avoid selecting guides that have predicted off-targets directly followed by a PAM, 
high global sequence similarity, mismatches only in the PAM distal region and those that do not have maximal 
consecutive mismatches10. However, when designing an sgRNA to targeting a particular disease-causing muta-
tion there is no flexibility (other than guide length) to meet these criteria. Consequently, a guide-specific treat-
ment strategy is not suitable for targeting the mutant alleles which cause TGFBI corneal dystrophies, as an almost 
perfect off-target site exists in the form of the wild-type allele.
Although here, and in previous reports, a SNP-derived PAM approach has been shown to provide highly spe-
cific cleavage15, this can only be applied to PAM-generating mutations. In the case of TGFBI corneal dystrophies, 
of the 60 causative mutations less than a third generate a novel S. pyogenes PAM. Therefore, even if the problems 
associated with Cas9/sgRNA delivery at present were overcome, the majority of patients with TGFBI would not 
have mutations that could be directly targeted.
Cas9 S. pyogenes orthologues are not as well characterised, therefore their off-target profiles are not as well 
understood as the that of S. pyogenes. In addition to this, they have much more intricate PAMs that occur 
much less frequently in the genome, reducing the fraction of TGFBI mutations that will result in a novel PAM. 
Furthermore, our results highlight another concern; even though the mutant SNP generated a novel PAM a 
non-canonical PAM existed in the wild-type sequence (Fig. 5b), meaning allele-specific cleavage could not be 
achieved. If non-canonical PAMs are considered within the analysis the number of targetable mutations would 
be even further reduced.
It is clear that individual guides perform with different cleavage efficiencies and specificity profiles. It is unre-
alistic to suggest a 60 allele-specific guide system as an effective treatment for TGFBI corneal dystrophies. A need 
for a highly-specific catch-all approach is apparent.
Materials and Methods
Oligonucleotides. All oligonucleotides used in this study were purchased from Integrated DNA 
Technologies. Sequences are listed in Supplementary Table 2.
Constructs. The S. pyogenes Cas9 vector plasmid used was pSpCas9(BB)-2A-Puro (PX459) V2.0, a gift from Feng 
Zhang (Addgene plasmid # 62988).The S.aureus Cas9 vector plasmid used was pX601-AAV-CMV::NLS-SaCas9-NLS-
3xHA-bGHpA;U6::BsaI-sgRNA, a gift from Feng Zhang (Addgene plasmid # 61591). The mutant AsCpf1 used was 
kindly provided from Professor Feng Zhang, Broad Institute MIT. Wild-type TGFBI or mutant TGFBI guides were 
cloned into the various plasmids by standard molecular biology techniques. A detailed protocol is outlined by Ran et al.4. 
In brief, S. pyogenes Cas9 and mutant AsCpf1 were digested with BbsI (NEB Cat # R0539S) while S.aureus Cas9 was 
digested with BsaI (NEB Cat # R0535S). Guide sequences (shown in Supplementary Table 2) were annealed and cloned 
into the corresponding digested plasmid.
A firefly luciferase reporter plasmid was used to assess knockdown. The vector plasmid used was 
psiTEST-LUC-Target (York Bioscience Ltd, York, UK). 50 nucleotides of wild type TGFBI or mutant TGFBI 
sequence was cloned into the MCS by standard molecular biology techniques.
An expression construct for Renilla luciferase (pRL-CMV, Promega, Southampton, UK) was used for the 
dual-luciferase assay to normalize transfection efficiency. In brief, psiTEST-LUC-Target was digested with 
NheI and KpnI (NEB Cat # R0131S and # R0142S). Human wild-type or mutant TGFBI sequences (shown in 
Supplementary Table 2) were annealed and cloned into the digested plasmid.
Off-target analysis. Off-target and on-target scores were calculated using the ‘Optimised CRISPR Design 
Tool’, available online by the Zhang lab, MIT 2013 and ‘Benchling’s CRISPR Tool’ available online by Benchling.
Dual-Luciferase Assay. A dual luciferase assay was used to determine the potency and allele specificity 
of the different guides previously described. HEK AD293 cells (Life Technologies) were co-transfected using 
Lipofectamine 2000 (Life Technologies) with a CRISPR plasmid, a firefly luciferase reporter plasmid and Renilla 
Luciferase expression plasmid. Cells were incubated for 72 hours, before being lysed and the activities of both 
Firefly luciferase and Renilla luciferase quantified.
Intrastromal Injection. Animals were used for the following experiments in accordance with the UK 
Animal Welfare Act; the experiments were approved by the Home Office (Scotland) and the DHSSPS (Northern 
Ireland). Prior to intrastromal injection of CRISPR components, mice were anaesthetised by intraperitoneal 
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injection with a mix of Hypnorm (25 mg/kg; VetaPharma Ltd, Leeds, UK) and Hypnovel (25 mg/kg; Roche, 
Hertfordshire, UK). In addition, topical anaesthetic (0.5%w/v Tetracaine Hydrochloride; Bausch & Lomb, 
Aubenas, France) was applied to the eye. Following injection, mice were allowed to recover in a heated cabinet 
and monitored for adverse effects until the anesthesia had worn off fully. Cas9/sgRNA constructs were delivered 
to the mouse cornea by intrastromal injection, as previously described (Courtney et al.8). Both a guide targeted 
to Luc2 (sgLuc2 - right eye) and a non-specific control guide (sgNSC - left eye) were injected intrastromally in a 
total volume of 4 µl of PBS at a concentration of 500ng/µl.
Live animal imaging. All mice used for live imaging were aged between 12 and 25 weeks old. For imaging, 
mice were anaesthetised using 1.5–2% isoflurane (Abbott Laboratories Ltd., Berkshire, UK) in ~1.5 l/min flow of 
oxygen. A mix of luciferin substrate (30 mg/ml D-luciferin potassium salt; Gold Biotechnology, St. Louis, USA) 
mixed 1:1 w/v with Viscotears gel (Novartis, Camberley, UK) was dropped onto the eye of heterozygous Krt12 
+/luc2 transgenic mice immediately prior to imaging. A Xenogen IVIS Lumina (Perkin Elmer, Cambridge, UK) 
was used to quantify luminescence. Live images of mice (n = 4) were taken every 24 hours for 7 days, then once 
every week thereafter for six weeks (42 days) in total. Quantification of luciferase inhibition was determined by 
calculating the right/left ratio, with values normalised to those at day 0 (as 100%).
In vitro digestion of circular plasmid and DNA template with purified S. pyogenes Cas9. A 
double-stranded DNA template was prepared by amplifying a region of the luciferase reporter plasmid con-
taining the desired sequence using the following primers: 5′-ACCCCAACATCTTCGACGCGGGC-3′ and 
3′-TGCTGTCCTGCCCCACCCCA-5′. A cleavage reaction was set up by incubating 30 nM S. pyogenes Cas9 
nuclease (NEB UK) with 30 nM synthetic sgRNA (Synthego) for 10 minutes at 25 °C. The Cas9:sgRNA complex 
was then incubated with 3 nM of DNA template at 37 °C for 1 hour. Fragment analysis was then carried out on a 
1% agarose gel.
Statistical analysis. All error bars represent the S.E.M. unless stated otherwise. Significance was calculated 
using a Mann-Whitney test. Statistical significance wasset at p < 0.05. Variance was calculated among groups and 
deemed to be similar.
Data availability. No datasets were generated or analysed during the current study.
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